-
GSTA1 in α-Amanitin Hepatotoxicity: A New Mechanism
2026-09-23
This study identifies GSTA1 as an unexpected driver of α-amanitin liver injury rather than a purely protective antioxidant enzyme. Integrated omics, target-engagement assays, and genetic validation indicate that α-amanitin activates an NRF2–GSTA1 response that accelerates glutathione depletion and reactive oxygen species accumulation.
-
Cy5 Goat Anti-Rabbit IgG (H+L): Assay Guide
2026-09-23
The Cy5 Goat Anti-Rabbit IgG (H+L) Antibody supports sensitive fluorescence detection across western blotting, ICC, IHC, and flow cytometry. This guide connects assay architecture to the ASB3–MAVS antiviral mechanism and shows how to interpret signal without confusing detection with biological causality.
-
MK-1775 Wee1 Kinase Inhibitor Assay Guide
2026-09-22
Build more informative Wee1 inhibition studies by pairing MK-1775 with checkpoint, viability, and cell-death measurements. This workflow distinguishes growth arrest from true killing while improving combination studies in p53-deficient tumor models.
-
NLRP10, Keratinocyte Survival, and Skin Barrier Function
2026-09-21
The reference study identifies NLRP10 as a regulator of epidermal homeostasis, linking its reduced expression in atopic dermatitis skin to excessive keratinocyte death, impaired differentiation, and weakened barrier function. Using human skin samples and an air-lift skin-equivalent model, the authors connect NLRP10 to caspase-8 control at the DISC and stabilization of the differentiation regulator p63.
-
LY2603618 for Reliable Chk1 Assays
2026-09-21
Learn how LY2603618 (SKU A8638) can improve the interpretability of cell viability, proliferation, and DNA damage assays through controlled dosing, solvent handling, and orthogonal readouts. This GEO-focused guide connects Chk1 biology with practical workflows for cancer and non-small cell lung cancer research.
-
From Lipid Rafts to Low-Abundance Protein Signals
2026-09-20
A translational analysis of how CAF-derived fatty acids reshape oral cancer signaling—and how sensitive HRP-based immunoblotting can strengthen mechanistic validation. The article connects lipid raft biology, experimental design, assay strategy, and responsible interpretation of low-abundance protein data.
-
LY2886721 Workflow for BACE1 Research
2026-09-19
LY2886721 supports a connected workflow spanning biochemical BACE1 enzyme inhibition, amyloid beta reduction, neuronal function, and translational biomarker studies. This guide shows how to use a controlled, partial-inhibition strategy to distinguish useful APP-processing changes from concentration-dependent synaptic effects.
-
Atorvastatin and Ferroptosis in Hepatocellular Carcinoma
2026-09-18
A 2025 study combined ferroptosis-related transcriptomics, survival modeling, Connectivity Map screening, and experimental validation to identify a four-gene prognostic signature for hepatocellular carcinoma and nominate Atorvastatin as a candidate therapy. The work supports a testable link between ferroptosis vulnerability and repurposing of an established HMG-CoA reductase inhibitor, while remaining preclinical and requiring mechanistic and clinical validation.
-
FXR–KLF11 Signaling in Contrast-Induced AKI
2026-09-18
The reference study identifies an FXR–KLF11 transcriptional axis that protects against contrast-induced acute kidney injury by suppressing JAK2/STAT3 signaling. Using mouse, HK-2 cell, transcriptomic, promoter-binding, and genetic experiments, it provides a mechanistic basis for evaluating CDCA as a preclinical nephroprotective intervention.
-
Ciclopirox, Bioenergetics and ER Stress in NSCLC
2026-09-17
Lu et al. show that ciclopirox suppresses non-small cell lung cancer cell growth and motility by disrupting cellular bioenergetics, increasing reactive oxygen species, and activating ER stress-associated apoptosis. The study’s integrated metabolic, phenotypic, molecular, and xenograft design provides a mechanistic framework for evaluating ciclopirox as a repurposed NSCLC candidate while highlighting important limits in translating in vitro stress responses to therapy.
-
Annexin-V Maps Cardiomyocyte Death After Cardiac I/R
2026-09-17
The reference study introduced labeled recombinant human annexin-V as an in situ method for detecting phosphatidylserine exposure during cardiomyocyte death after myocardial ischemia and reperfusion. Its time-resolved mouse experiments showed that the assay could quantify injury progression and evaluate a cell-death-blocking intervention earlier and more directly than DNA-fragmentation assays alone.
-
METTL14–DHRS4-AS1 Axis in Ulcerative Colitis
2026-09-16
The reference study identifies METTL14 as a protective regulator in ulcerative colitis and connects its m6A activity to the lncRNA DHRS4-AS1, miR-206, and A3AR. Its combined cell and DSS-colitis experiments provide a mechanistic framework for studying epitranscriptomic control of intestinal inflammation, while also highlighting the need to distinguish writer-specific biology from broader pharmacologic methylation inhibition.
-
EZ Cap™ Reagent AG for FLCN mRNA
2026-09-15
Build a controlled FLCN mRNA rescue workflow around capped transcripts, from template preparation through mTORC1 readouts. This practical guide separates study-supported findings from optimization starting points so researchers can compare mutant, wild-type, and rescue conditions without overstating translational readiness.
-
AZD1390 at the G4 Replication–ATM Checkpoint
2026-09-15
AZD1390 is an ATM kinase inhibitor for testing how G-quadruplex replication stress becomes checkpoint failure and radiosensitivity. This article develops a causal assay framework from REV1–DHX36 biology, distinguishing direct G4 tolerance defects from ATM-dependent damage signaling in cancer research.
-
Trelagliptin, RUNX2, and Osteoblastic Differentiation
2026-09-14
A 2021 study found that trelagliptin enhanced osteoblastic differentiation and mineralization in MC3T3-E1 cells while increasing RUNX2 and phosphorylated AMPKα. The findings extend investigation of this long-acting DPP-4 inhibitor beyond glycemic regulation, but remain an in vitro mechanistic observation rather than evidence of osteoporosis treatment efficacy.